Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in Girls Living With HIV

Jason Brophy; Ari Bitnun; Ariane Alimenti; Normand Lapointe; Lindy Samson; Stanley Read; Christos Karatzios; Simon Dobson; Erin Moses; Sandra Blitz; Nancy-Grace Lipsky; Gina Ogilvie; Sharon Walmsley; Janet Raboud; Deborah Money; HPV in HIV Study Group

doi:10.1097/INF.0000000000001874

Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in Girls Living With HIV

Pediatr Infect Dis J. 2018 Jun;37(6):595-597. doi: 10.1097/INF.0000000000001874.

Authors

Jason Brophy¹, Ari Bitnun^{2

3}, Ariane Alimenti⁴, Normand Lapointe^{5

6}, Lindy Samson¹, Stanley Read^{2

3}, Christos Karatzios^{7

8}, Simon Dobson⁴, Erin Moses⁹, Sandra Blitz¹⁰, Nancy-Grace Lipsky⁹, Gina Ogilvie^{9

11

12

13}, Sharon Walmsley^{10

14

15}, Janet Raboud^{10

16}, Deborah Money^{9

11

14}; HPV in HIV Study Group

Affiliations

¹ From the Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada.
² Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada.
³ Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.
⁴ Division of Infectious and Immunological Diseases, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
⁵ Department of Pediatrics, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.
⁶ Centre maternel et infantile sur le SIDA, CHU Sainte-Justine, Montreal, Quebec, Canada.
⁷ Department of Paediatrics, Centre hospitalier universitaire Sainte-Justine, Université de Montréal, Montreal, Quebec, Canada.
⁸ Department of Paediatrics, Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, Canada.
⁹ Women's Health Research Institute, BC Women's Hospital and Health Centre, Vancouver, British Columbia, Canada.
¹⁰ Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada.
¹¹ Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
¹² BC Centre for Disease Control, Vancouver, British Columbia, Canada.
¹³ Department of Family Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
¹⁴ Canadian Institutes of Health Research (CIHR) Canadian HIV Trials Network (CTN), Vancouver, British Columbia, Canada.
¹⁵ Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
¹⁶ Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

PMID: 29278613
DOI: 10.1097/INF.0000000000001874

Abstract

We evaluated quadrivalent human papillomavirus vaccine seroresponses among 35 girls living with HIV (9-13 years of ages) and compared with data on girls without HIV, as part of a subgroup analysis. The quadrivalent human papillomavirus vaccine was safe and well tolerated. However, antibody response was significantly lower in girls living with HIV relative to girls without HIV. HIV virologic suppression predicted better antibody response.

Publication types

Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Antibodies, Viral / blood
CD4 Lymphocyte Count
Canada
Child
Female
HIV Infections / virology*
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / adverse effects
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / immunology*
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / therapeutic use
Humans
Immunogenicity, Vaccine*
Longitudinal Studies
Papillomavirus Infections / prevention & control*
Prospective Studies

Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in Girls Living With HIV

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

Associated data

Grants and funding